How Does iKang Group Company Work and Make Money?

iKang provides health checkup centers, lab and imaging diagnostics, advanced cancer and cardiovascular screening, genomic tests, and the iKang AI plus analytics platform; it also sells subscription memberships and B2B corporate health programs.

Customers include >30,000 corporate clients, millions of individual consumers, high-net-worth clients seeking executive checks, insurers (for reimbursement partnerships), and hospital/clinic partners in its franchise and referral network.

Clients gain faster, consolidated screening, higher diagnostic consistency via AI, and actionable prevention plans that lower absenteeism and long-term medical costs; insurers and employers gain measurable risk stratification for workforce health.

Customers pick iKang for one-stop convenience, standardized quality across centers, AI-backed diagnostic consistency, and integrated corporate programs that simplify billing and insurer reimbursement.

For fiscal 2025 iKang reported consolidated revenue of RMB 4.2 billion, gross margin near 46%, and adjusted EBITDA margin around 12%; the network operated over 1,200 owned and franchised centers and served an estimated 3.8 million checkup clients in the year.

In 2025 diagnostic testing and imaging contributed approx 55% of service revenue, corporate contracts and memberships 30%, and ancillary services (telehealth, franchising, lab reagents) 15%. Average revenue per corporate client rose to RMB 45,000 annually for large accounts.

iKang targets higher-margin genomic and AI-read imaging services, expands insurer reimbursement partnerships, increases franchise rollouts to lower capex per center, and upsells subscription plans to corporate clients to raise lifetime value.

Key risks: regulatory limits on private health services, pricing pressure from hospitals, insurer reimbursement negotiation, and tech validation needs for AI diagnostics that affect adoption and revenue recognition timing.

Annual employee checkup contracts account for roughly 75% of 2025 revenue, providing recurring, multi-year cash flow through large-volume B2B agreements with employers and insurers.

High-margin deep-screening upsells – liquid biopsy and advanced metabolic panels – can price from $1,500 per test versus basic packages near $100; dental, vaccinations, and health-management subscriptions add recurring B2C revenue.

iKang uses volume pricing for corporate contracts, point-of-service pricing for exams and tests, and subscription fees for chronic care management; insurer reimbursements and bundled packages increase uptake and ARPU.

Scale of corporate clients drives fixed-cost coverage and throughput; conversion of screened individuals into high-ticket diagnostic tracks and subscription services is the main margin lever for 2025 – 2026.

iKang Group leverages a nationwide medical examination network that processed over tens of millions of records by 2025, creating a data moat that improves AI-driven diagnostics and upsell rates for repeat customers.

Partnerships with insurers, employers, and e-commerce platforms provide steady referral volume and reimbursement channels; Alibaba cloud and retail referrals lower customer-acquisition costs versus indie clinics.

Revenue depends on regulatory permissions for handling health data and inspection licenses; China's tightening privacy rules (post-2021 Personal Information Protection Law enforcement through 2024 – 2025) raise compliance costs and restrict some data monetization paths.

The model looks resilient due to demographic tailwinds from China's aging population and recurring corporate contracts, but profitability is exposed to rising skilled labor costs and tighter data governance; automation and AI are the key mitigation levers.